Zacks Investment Research on MSN
Merck indicates better growth visibility in post-Keytruda LOE period
Merck MRK announced better-than-expected fourth-quarter 2025 results earlier this month. The company beat estimates for both ...
Stocktwits on MSN
How Merck is preparing for the patent cliff of its blockbuster cancer drug Keytruda
Merck posted a modest Q4 earnings beat with adjusted EPS of $2.04 on $16.4 billion in revenue. ・The company is planning ...
Merck & Co., Inc. is rated a Buy due to robust asset portfolio, strong shareholder return, and buybacks. Learn more about MRK stock here.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SC™ (pembrolizumab injection), a new subcutaneous formulation of ...
Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total ...
Keytruda Qlex must be administered by a health care provider. The Food and Drug Administration (FDA) has approved Keytruda Qlex ™ (pembrolizumab and berahyaluronidase alfa-pmph) for patients aged 12 ...
KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results